First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors

被引：0
作者：
Daud, Adil
Albany, Costantine
Velcheti, Vamsidhar
Hauke, Ralph J.
Ahnert, Jordi Rodon
Karp, Daniel D.
Tsimberidou, Apostolia Maria
Cohen, Julia Wanda
Schmidt, Emmett V.
Wang, Jieyi
Chan, C. Hubert
Fu, Siqing
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Horizon Oncol & Res Ctr, Lafayette, IN USA
[3] NYU, New York, NY USA
[4] Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[5] Nebraska Canc Specialists, Omaha, NE USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Merck Co Inc, Rahway, NJ USA
[8] Lyvgen Biopharma, Shanghai, Peoples R China
[9] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2525
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
    Moreno, Victor
    Perets, Ruth
    Peretz-Yablonski, Tamar
    Fourneau, Nele
    Girgis, Suzette
    Guo, Yue
    Hellemans, Peter
    Verona, Raluca
    Pendas, Natalia
    Xia, Qi
    Geva, Ravit
    Calvo, Emiliano
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 93 - 104
  • [42] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] FIRST-IN-HUMAN PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND INITIAL CLINICAL ACTIVITY OF DUOBODY®-CD40x4-1BB (GEN1042) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Johnson, Melissa
    Lopez, Juanita
    LoRusso, Patricia
    Bauman, Jessica
    Haggstrom, Daniel
    Lagkadinou, Eleni
    Bajaj, Gaurav
    Tureci, Ozlem
    Adams, Homer, III
    Sahin, Ugur
    Fu, Yali
    Ahmadi, Tahamtan
    Rohrberg, Kristoffer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A525 - A525
  • [44] Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
    Kyi, Chrisann
    Van Dongen, Marloes
    Rottey, Sylvie
    Bermejo, Ignacio Melero
    Mittag, Diana
    Gouveia, Dane
    Bol, Kees
    Yan, Chris
    Joe, Andrew K.
    Laus, Gianluca
    Moreno, Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results
    Siu, Lillian L.
    Yap, Timothy A.
    Genta, Sofia
    Pennock, Gregory
    Hicking, Christine
    You, Xiaoli
    Mukker, Jatinder K.
    Locatelli, Giuseppe
    Tolcher, Anthony W.
    CANCER RESEARCH, 2023, 83 (08)
  • [46] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors
    Naing, Aung
    Gelderblom, Hans
    Gainor, Justin F.
    Forde, Patrick M.
    Butler, Marcus
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Schellens, Jan H. M.
    Soria, Jean-Charles
    Taylor, Matthew H.
    Silva, Antonio P.
    Li, Zhonggai
    Bilic, Sanela
    Cameron, Scott
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
    Postel-Vinay, Sophie
    Lam, Vincent K.
    Ros, Willeke
    Bauer, Todd M.
    Hansen, Aaron R.
    Cho, Daniel C.
    Stephen Hodi, F.
    Schellens, Jan H. M.
    Litton, Jennifer K.
    Aspeslagh, Sandrine
    Autio, Karen A.
    Opdam, Frans L.
    McKean, Meredith
    Somaiah, Neeta
    Champiat, Stephane
    Altan, Mehmet
    Spreafico, Anna
    Rahma, Osama
    Paul, Elaine M.
    Ahlers, Christoph M.
    Zhou, Helen
    Struemper, Herbert
    Gorman, Shelby A.
    Watmuff, Maura
    Yablonski, Kaitlin M.
    Yanamandra, Niranjan
    Chisamore, Michael J.
    Schmidt, Emmett, V
    Hoos, Axel
    Marabelle, Aurelien
    Weber, Jeffrey S.
    Heymach, John, V
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (03)
  • [48] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
    Xue, Junli
    Sun, Yuping
    Li, DaPeng
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
    Xu, Jian-Ming
    Jia, Ru
    Wang, Yan
    Liu, Rongrui
    Zhao, Chuanhua
    Zhou, Hui
    Xu, Linxinyu
    Kong, Xuan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
12345